NEPHROCARE HEALTH SERV L NEPHROPLUS NSEPHARMA
Healthcare · Medical Care Facilities · India
Nephrocare Health Services Limited operates a chain of kidney care clinics that provides dialysis healthcare services with dialysis centres in India, Uzbekistan, Nepal, Kingdom of Saudi Arabia, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. Nephrocare Health Services Limited was incorporated in 2009 and is based in Hyderabad, India.
READ MORE ›₹598.70
+27.05% 1Y
Market & Price
Market Cap
₹6,007.40 Cr
Current Price
₹598.70
High / Low (52W)
₹649.70 / ₹449.15
Beta
-
Valuation
Stock P/E
74.10
Industry PE
37.60
Forward P/E
29.33
PEG Ratio
-
Book Value
₹391.25
Price to Book
1.53
P/S
6.01
EV/EBITDA
24.94
Dividend Yield
-
Profitability & Returns
ROCE
13.46%
ROE
9.04%
ROA
6.91%
Profit Margin
7.69%
Op Margin
10.51%
EPS (Latest Qtr)
₹2.96
EPS (TTM)
₹8.08
Balance Sheet & Liquidity
Debt/Equity
0.07
Quick Ratio
2.48
Current Ratio
2.80
Debt
₹79.71 Cr
Total Assets
₹1,470.87 Cr
Current Assets
₹839.17 Cr
Working Capital
₹539.76 Cr
Ownership
Promoter Holding
54.73%
Chg in Prom Hold
-
FII / Inst Holding
32.29%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
₹5,660.96 Cr
Total Revenue (TTM)
₹998.85 Cr
EBITDA
₹226.96 Cr
Free Cash Flow
₹89.72 Cr
Operating Cash Flow
₹232.58 Cr
Shares Outstanding
₹10.03 Cr
Gross Margin
40.86%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
34.07%
Profit 5Y
250.60%
Revenue (YoY)
21.20%
Earnings (YoY)
0.30%
PROS
- Compounding revenue at 34.1% over 5 years.
- Profit CAGR of 250.6% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 74.1.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NEPHROPLUS NEPHROCARE HEALTH SERV L NSEPHARMA | 598.70 | 74.10 | ₹6,007.40 Cr | - | 13.46% | 9.04% | 34.07% | 250.60% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Ad space
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 197.26 Cr | 219.19 Cr | 259.73 Cr | 265.62 Cr |
| Cost of Revenue | 120.32 Cr | 130.11 Cr | 152.29 Cr | 156.09 Cr |
| Gross Profit | 76.94 Cr | 89.08 Cr | 107.43 Cr | 109.53 Cr |
| Operating Expenses | 51.01 Cr | 57.16 Cr | 68.43 Cr | 81.61 Cr |
| Operating Income | 25.92 Cr | 31.93 Cr | 39.00 Cr | 27.92 Cr |
| EBITDA | 49.46 Cr | 55.41 Cr | 64.18 Cr | 62.24 Cr |
| Interest Expense | 4.85 Cr | 6.12 Cr | 5.96 Cr | 3.18 Cr |
| Pretax Income | 26.43 Cr | 29.92 Cr | 36.36 Cr | 33.22 Cr |
| Tax Provision | 6.33 Cr | 5.05 Cr | 4.12 Cr | 2.85 Cr |
| Net Income | 20.11 Cr | 24.87 Cr | 32.24 Cr | 30.37 Cr |
| Diluted EPS | 2.00 | 2.48 | 3.35 | 2.96 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 414.52 Cr | 539.55 Cr | 755.81 Cr | 998.85 Cr |
| Cost of Revenue | - | 311.03 Cr | 368.69 Cr | 474.90 Cr | 590.72 Cr |
| Gross Profit | - | 103.50 Cr | 170.86 Cr | 280.91 Cr | 408.12 Cr |
| Operating Expenses | - | 99.85 Cr | 117.38 Cr | 186.74 Cr | 271.83 Cr |
| Operating Income | - | 3.64 Cr | 53.47 Cr | 94.17 Cr | 136.30 Cr |
| EBITDA | - | 52.87 Cr | 107.05 Cr | 180.74 Cr | 248.38 Cr |
| Interest Expense | - | 14.59 Cr | 19.00 Cr | 20.83 Cr | 60.24 Cr |
| Pretax Income | - | -8.59 Cr | 33.16 Cr | 87.44 Cr | 97.47 Cr |
| Tax Provision | - | 3.20 Cr | -1.97 Cr | 20.34 Cr | 20.63 Cr |
| Net Income | - | -11.79 Cr | 35.13 Cr | 67.10 Cr | 76.84 Cr |
| Diluted EPS | - | -1.17 | 3.50 | 6.69 | 8.10 |
Compounded Sales Growth
| 5 Years: | 34.07% |
| 1 Year: | 21.20% |
Compounded Profit Growth
| 5 Years: | 250.60% |
| 1 Year: | 0.30% |
Stock Price Performance
| 1 Year: | +27.05% |
| 6 Months: | - |
| 3 Months: | +7.13% |
| 1 Month: | +10.95% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 666.23 Cr | 806.02 Cr | 996.46 Cr | 1,470.87 Cr |
| Current Assets | - | 324.25 Cr | 390.03 Cr | 545.36 Cr | 839.17 Cr |
| Cash & Equivalents | - | 13.19 Cr | 61.15 Cr | 125.82 Cr | 123.89 Cr |
| Inventory | - | 26.27 Cr | 25.91 Cr | 26.62 Cr | 33.04 Cr |
| Receivables | - | 158.50 Cr | 202.67 Cr | 266.42 Cr | 316.89 Cr |
| Total Liabilities | - | 277.60 Cr | 392.31 Cr | 412.35 Cr | 354.37 Cr |
| Current Liabilities | - | 174.61 Cr | 242.59 Cr | 283.89 Cr | 299.41 Cr |
| Long Term Debt | - | 81.48 Cr | 123.24 Cr | 96.00 Cr | 4.70 L |
| Total Debt | - | 213.73 Cr | 267.84 Cr | 257.78 Cr | 79.71 Cr |
| Total Equity | - | 388.63 Cr | 413.71 Cr | 584.11 Cr | 1,116.49 Cr |
| Shares Outstanding | - | 10.03 Cr | 10.03 Cr | 10.03 Cr | 10.03 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 11.27 Cr | 72.28 Cr | 135.35 Cr | 232.58 Cr |
| Investing Cash Flow | - | -78.21 Cr | -50.66 Cr | -125.07 Cr | -410.44 Cr |
| Financing Cash Flow | - | 59.97 Cr | 26.74 Cr | 54.37 Cr | 157.11 Cr |
| Capital Expenditure | - | -73.74 Cr | -80.00 Cr | -100.80 Cr | -119.36 Cr |
| Free Cash Flow | - | -62.47 Cr | -7.72 Cr | 34.55 Cr | 113.22 Cr |
| Net Change in Cash | - | -6.97 Cr | 48.36 Cr | 64.64 Cr | -20.75 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 25.0% | 31.7% | 37.2% | 40.9% |
| Operating Margin % | - | 0.9% | 9.9% | 12.5% | 13.6% |
| Net Margin % | - | -2.8% | 6.5% | 8.9% | 7.7% |
| ROE % | - | -3.0% | 8.5% | 11.5% | 6.9% |
| ROCE % | - | 0.7% | 9.5% | 13.2% | 11.6% |
Shareholding Pattern
Insiders
54.73%
Institutions
32.29%
Public Float
71.32%
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NEPHROPLUS
No recent headlines available.